BC undergraduate 'wunderkind' racks up five national awards for science research

April 25, 2006

CHESTNUT HILL, MA (4-25-06) - Aspiring cancer researcher Elizabeth O'Day of Boston College is well on her way to becoming one of the nation's most recognized female scientists -- and she hasn't even graduated yet.

O'Day, currently a senior, has achieved what no one at Boston College -- and few, if any, at other universities have done: she has won five of the nation's most coveted academic awards for her scientific research efforts. After earning Beckman and Goldwater fellowships as a sophomore and junior respectively, this year O'Day has received a Winston Churchill Scholarship to study at Cambridge University, a Fulbright grant and a National Science Foundation Graduate Research Fellowship.

The Braintree, Mass. native is studying cell enzymes that she hopes will contribute to the development of a new class of inhibitors that in turn may lead to a new class of anti-cancer drugs

And, in an equally passionate effort to debunk assertions of female inadequacies in the sciences and to encourage local female high school students to consider a science career, O'Day earlier this year launched at Boston College an initiative of her own design called "Women in Science & Technology." The month-long series brought students from three local high schools to Boston College for research, lectures, field excursions and the opportunity to meet both mentors and role models across scientific disciplines.

The program stems from O'Day's desire to share her own experience as a woman in science, which the BC senior says has been a source of both inspiration and opportunity.

"Last year when I was invited to speak about science at a local high school, I was disappointed to learn that many of the girls in the audience said they found science to be too boring or difficult," said O'Day. "So I decided that I wanted to do something to give teenage girls a better understanding of the scientific process and ultimately to excite them about choosing science as a major and a career."

O'Day has found her own scientific work to be rewarding in more ways than one.

The Winston Churchill Scholarship, which she received in January, offers promising young American scientists the opportunity to establish international contacts while studying at one of Britain's premier science centers. It will support her graduate work at Churchill College of Cambridge University. Her Fulbright Scholarship offered similar opportunities for graduate study in India. In 2005, O'Day landed a coveted Goldwater Scholarship, considered the premier undergraduate science fellowship, and was chosen to present her research at the Euroregionale Conference of the American Chemical Society German Exchange Program in Berlin. The previous year, as a sophomore, she won a highly competitive Beckman Scholarship, which funds intensive research experiences for exceptional undergraduates.

Far from resting on her laurels, however, O'Day is now fully invested in her quest to promote science to younger women. "BC has also taught me that I'm not only responsible for myself and my research, but for society as well," said O'Day. "I am so grateful for what science has brought to my life that I want show others the opportunities it offers."

In her limited spare time, O'Day is also the captain and starting fullback on BC's women's rugby team where she has earned the nickname "The Brick Wall," for her fearless tackles.

Her passion for her scientific research prevails, however. "I'm grateful to be able to help develop research that is not only exciting but has real world application," said O'Day. "Like many people I have seen first hand the devastation when a loved one is diagnosed with cancer. By working on this project I have been given an opportunity to help combat this disease."

When she returns from graduate work in England, she plans to pursue a doctorate in chemical biology.

Boston College

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.